| Abstrakt: |
A meta-analysis conducted by researchers at Shiraz University of Medical Sciences compared the effectiveness of two types of stem cell therapy, bone-marrow mononuclear cell (BMMNC) and mesenchymal stromal cell (MSC), in patients with chronic heart failure. The analysis included 36 randomized controlled trials and found that both types of stem cells resulted in a significant improvement in left ventricular ejection fraction (LVEF), a measure of heart function. However, stem cell therapy did not lead to a significant change in the risk of major adverse cardiovascular events (MACE). The researchers concluded that future trials should focus on the impact of stem cell transplantation on clinical outcomes in heart failure patients. [Extracted from the article] |
